Two Onc Docs

This podcast episode focuses on testicular cancer, covering important details on staging, risk categories, and treatment options for both seminoma and non-seminoma. It also discusses the significance of tumor markers, symptoms, workup, and the different stages of testicular cancer. Treatment options include surveillance, surgery, radiation, and chemotherapy regimens. The episode emphasizes the importance of awareness for growing teratoma syndrome and potential toxicities associated with chemotherapy.

This podcast provides high yield concepts and facts for the oncology portion of the IM Boards. Topics covered include cancer screening recommendations, prevention strategies, treatment options for breast and colon cancer, mismatch repair enzymes and immunotherapy for MSI high cases, and the long-term effects of chemotherapy.

The podcast discusses important topics for the ABIM internal medicine exam, focusing on hematology. It explores various disorders related to erythrocytes, leukocytes, platelets, coagulation, transfusion medicine, and heme malignancies. Specific cases are discussed, including evaluation of a fatigued patient with a history of breast cancer, hematological disorders such as APL and TTP, chronic myeloid leukemia and G6PD deficiency. Additionally, vignettes on acquired factor eight inhibitor and post-transfusion purpura are explored, along with insights on appropriate treatment options.

The podcast discusses the treatment options for castrate sensitive and resistant prostate cancer, including oral anti-androgen medications, docetaxel chemotherapy, radium-223, and cabazitaxel. It also explores the importance of understanding drugs and genetic testing, and discusses second-line treatments such as chemo with Kepazzi-Taxel and immunotherapy with Pembrolycumab. Additionally, it covers monitoring strategies using PSA levels and imaging, treatment options for small cell prostate cancer, castrate resistance, and genetic testing for stage four patients.

Learn about localized prostate cancer, including diagnostic work-up, staging, and treatment. Understand the role of bone scans in staging and the treatment options available. Discover the management of localized prostate cancer and the importance of post-treatment surveillance. Explore the basics of staging, treatment options, and monitoring PSA doubling time during surveillance.

This podcast explores the causes, diagnostic work-up, and treatment options for aplastic anemia. It discusses pathophysiology, presentation, and treatment options, as well as alternative treatments when initial therapies fail. The prevalence of PNH clones in aplastic anemia patients and treatment options for symptomatic patients are also discussed.

This podcast discusses small cell lung cancer, including risk factors, diagnosis, staging, and treatment options. They emphasize early detection and the limitations of treatment for relapsed disease. They explore the characteristics, pathology, and symptoms of small cell lung cancer. Starting chemotherapy immediately after diagnosis is crucial and they discuss staging imaging techniques. Treatment approaches for both limited and extensive stage small cell lung cancer are covered, including surgery, radiation, chemotherapy, and immunotherapy.

Today’s episode is focusing on what you need to know regarding myelodysplastic syndrome (MDS) - diagnosis, risk stratification and treatment options for low risk as well as high risk MDS.

Topics discussed in this episode include rising cases of anal squamous cell carcinoma in the US, risk factors like HPV infection and smoking, diagnostic workup and staging of anal cancer, treatment regimens for different stages, alternative treatment options and surveillance protocol, and the role of immunotherapy in anal cancer treatment.

This podcast discusses risk factors, diagnostic work-up, staging, and treatment options for melanoma. It covers excision margins, surgical management, and adjuvant therapy. The episode also explores staging criteria for metastatic melanoma, treatment options, side effects, and monitoring. Additionally, it mentions BRF and MEK inhibitors for metastatic melanoma, rare subtypes of melanoma, and key points for the boards.